Independent vs. Chain-Owned Dialysis Centers: What the CMS Data Shows

Most dialysis patients don't choose who owns their clinic. They choose the clinic that is closest, has an open chair, and accepts their insurance. But ownership matters more than most patients realize — and the government publishes the data to prove it.

What the numbers actually say

The CMS Dialysis Facility Compare dataset covers every Medicare-certified dialysis facility in the United States. When you look at transplant referral rates sorted by ownership type, a pattern emerges consistently across states:

Independent dialysis facilities refer patients for kidney transplant evaluation at meaningfully higher rates than chain-owned facilities on average. The gap varies by market, but researchers who have controlled for patient demographics and comorbidities still find a statistically significant difference.

A series of studies published in JAMA found that when DaVita or Fresenius acquired an independent clinic, transplant referral rates at that clinic dropped by approximately 10% within the first few years following acquisition. Patient survival rates and hospitalization rates also worsened in the post-acquisition period.

Why this happens

The financial incentive is not complicated. A dialysis patient generates revenue three times a week, every week, for years. A successful kidney transplant ends that revenue stream permanently. Independent clinics, which are typically owned by nephrologists or small groups, generally have less financial pressure to keep patients on dialysis indefinitely. Their incentives are more aligned with the patient's long-term interest.

Chain-owned clinics are not necessarily providing inferior care intentionally. The effect is likely subtler: fewer proactive conversations about transplant candidacy, longer timelines for referral paperwork, less integration with transplant centers. But the cumulative result shows up in the data.

What to do with this information

Looking at CMS data for a specific facility, there are a few numbers that matter most when evaluating chain vs. independent performance:

Transplant referral rate — What percentage of eligible patients have been referred for transplant evaluation? Compare the facility you are evaluating to the state average and to nearby independent facilities.

Transplant waitlist rate — What percentage of patients are currently on the kidney transplant waiting list? This shows whether referrals are actually moving forward.

Standardized mortality ratio (SMR) — Is patient survival better or worse than expected given the facility's patient population?

None of these numbers should be read in isolation. A chain-owned facility with a 5-star CMS rating may outperform an independent clinic with a lower rating. The ownership flag is a signal worth examining, not a verdict.

The bigger picture

DaVita and Fresenius have paid over $1 billion in regulatory fines and settlements over the past decade. The FTC has scrutinized their noncompete agreements. The US Senate has held hearings. Peer-reviewed research has documented the outcomes patterns. None of this means every chain-owned clinic provides worse care — but it does mean patients have a legitimate interest in knowing who owns their facility and how that facility performs on the metrics that matter most.

Every facility page on DialysisCenterUSA shows ownership, star ratings, transplant referral rates, and patient outcome data side by side. Use it.